autologous bispecific BCMA/CD19-targeted CAR T cells GC012F

{
  "id": "MLC-T-ONC-011516",
  "term": "autologous bispecific BCMA/CD19-targeted CAR T cells GC012F",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of autologous T lymphocytes engineered to express two separate chimeric antigen receptors (CARs) targeting the tumor-associated antigens (TAAs) BCMA and CD19 and fused to as of yet not fully elucidated co-stimulatory domains, with potential immunostimulating and antineoplastic activities. Upon administration, the autologous bispecific BCMA/CD19-targeted CAR T cells GC012F specifically and simultaneously target and bind to tumor cells expressing BCMA and/or CD19. This induces selective toxicity in tumor cells that express BCMA and/or CD19. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in the survival of B lymphocytes and plasma cells. BCMA is found on the surfaces of B cells and is overexpressed on malignant plasma cells. CD19 is a B-cell-specific cell surface antigen overexpressed in B-cell lineage malignancies. The processing platform used, FasT CAR T, shortens the manufacturing time to produce the CAR T cells within 24 hours.",
  "synonyms": [
    "autologous anti-BCMA/CD19 dual CAR T cells GC012F",
    "autologous GC012F CAR-T cells"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/autologous-bispecific-bcma-cd19-targeted-car-t-cells-gc012f/"
}